BC Week In Review | Jun 2, 1997
Company News

PPD management update

Pharmaceutical Product Development Inc. (PPDI), Wilmington, N.C.   Business: Supply/Service   Hired: Mark Furth, Ph.D., as SVP of research and CSO of PPDI's newly formed research subsidiary; formerly president and CEO of Ingenex Inc. (Menlo...
BC Week In Review | Jun 2, 1997
Company News

Ingenex, PPD, Sarco Inc. deal

PPDI will acquire Sarco in a pooling of interests transaction involving 263,158 newly issued PPDI shares. PPDI, a contract research organization, also will acquire Ingenex's GSX system functional genomics technology, along with associated assets, for...
BioCentury | Jun 2, 1997
Strategy

Expanding the concept of contract research

Successful service providers anticipate customers' needs and make it easier for them to pay to have a job done rather than do the work in-house. CROs have done well by providing clinical development services, but...
BioCentury | Nov 4, 1996
Finance

The money's in the bank

Despite its common shares losing 42 percent of their value on Thursday due to a clinical hiccup, Carrington Laboratories (CARN) said it won't have to return to investors the $6.6 million it raised in a...
BioCentury | Jul 22, 1996
Finance

Billion-dollar biotech club

The frothiness of the biotech market at the close of the second quarter prompted Ebb & Flow to chart the larger-cap companies. Even with the recent sell-off in the sector, biotechnology still commands some healthy...
BC Week In Review | Jun 10, 1996
Company News

Titan other research news

TTNP's Ingenex Inc. subsidiary received a $750,000 Phase II SBIR grant from the National Institutes of Allergy and Infectious Diseases to develop a genetic approach to treat AIDS. The grant will fund research to discover...
BC Week In Review | Feb 27, 1995
Company News

Ingenex other research news

The Menlo Park, Calif., company received a $100,000 Phase I SBIR from the NIH to develop genetic suppressor elements (GSEs) to treat HIV and to identify human genes that may be involved in the disease....
BC Week In Review | Feb 6, 1995
Clinical News

Multidrug resistance gene therapy with MDR-1 gene inserted into patients' stem cells isolated from blood: Ingenex Inc., one of Titan's operating companies, has

Titan Pharmaceuticals Inc., Menlo Park, Calif.   Product: AN-9, based on butyric acid, which helps convert immature, rapidly dividing cells into differentiated cells, or to induce programmed cell death   Indication: Solid tumors   Status:...
BC Week In Review | Oct 17, 1994
Company News

Ingenex other research news

The company announced it licensed the RB-94 gene, whose discovery was published in the Proceedings of the National Academy of Sciences. The new form of the RB gene, called RB-94, allows intracellular build-up of a...
BC Week In Review | Sep 12, 1994
Clinical News

MDR-1 gene: Began pilot trial

Ingenex Inc. , Menlo Park, Calif.   Product: MDR-1 gene delivered ex vivo to blood precursor cells by a retroviral vector   Indication: Protection of marrow and blood in chemotherapy   Status: Began pilot trial in...
Items per page:
1 - 10 of 12
BC Week In Review | Jun 2, 1997
Company News

PPD management update

Pharmaceutical Product Development Inc. (PPDI), Wilmington, N.C.   Business: Supply/Service   Hired: Mark Furth, Ph.D., as SVP of research and CSO of PPDI's newly formed research subsidiary; formerly president and CEO of Ingenex Inc. (Menlo...
BC Week In Review | Jun 2, 1997
Company News

Ingenex, PPD, Sarco Inc. deal

PPDI will acquire Sarco in a pooling of interests transaction involving 263,158 newly issued PPDI shares. PPDI, a contract research organization, also will acquire Ingenex's GSX system functional genomics technology, along with associated assets, for...
BioCentury | Jun 2, 1997
Strategy

Expanding the concept of contract research

Successful service providers anticipate customers' needs and make it easier for them to pay to have a job done rather than do the work in-house. CROs have done well by providing clinical development services, but...
BioCentury | Nov 4, 1996
Finance

The money's in the bank

Despite its common shares losing 42 percent of their value on Thursday due to a clinical hiccup, Carrington Laboratories (CARN) said it won't have to return to investors the $6.6 million it raised in a...
BioCentury | Jul 22, 1996
Finance

Billion-dollar biotech club

The frothiness of the biotech market at the close of the second quarter prompted Ebb & Flow to chart the larger-cap companies. Even with the recent sell-off in the sector, biotechnology still commands some healthy...
BC Week In Review | Jun 10, 1996
Company News

Titan other research news

TTNP's Ingenex Inc. subsidiary received a $750,000 Phase II SBIR grant from the National Institutes of Allergy and Infectious Diseases to develop a genetic approach to treat AIDS. The grant will fund research to discover...
BC Week In Review | Feb 27, 1995
Company News

Ingenex other research news

The Menlo Park, Calif., company received a $100,000 Phase I SBIR from the NIH to develop genetic suppressor elements (GSEs) to treat HIV and to identify human genes that may be involved in the disease....
BC Week In Review | Feb 6, 1995
Clinical News

Multidrug resistance gene therapy with MDR-1 gene inserted into patients' stem cells isolated from blood: Ingenex Inc., one of Titan's operating companies, has

Titan Pharmaceuticals Inc., Menlo Park, Calif.   Product: AN-9, based on butyric acid, which helps convert immature, rapidly dividing cells into differentiated cells, or to induce programmed cell death   Indication: Solid tumors   Status:...
BC Week In Review | Oct 17, 1994
Company News

Ingenex other research news

The company announced it licensed the RB-94 gene, whose discovery was published in the Proceedings of the National Academy of Sciences. The new form of the RB gene, called RB-94, allows intracellular build-up of a...
BC Week In Review | Sep 12, 1994
Clinical News

MDR-1 gene: Began pilot trial

Ingenex Inc. , Menlo Park, Calif.   Product: MDR-1 gene delivered ex vivo to blood precursor cells by a retroviral vector   Indication: Protection of marrow and blood in chemotherapy   Status: Began pilot trial in...
Items per page:
1 - 10 of 12